Consequently, early-phase clinical trials are actively exploring CAR-T cells directed against alternative tumor-associated antigens (TAAs), including EGFR, EpCAM, and MUC1.EGFR-targeted CAR-T cells are currently under investigation in advanced solid tumors, including gastric cancer, aiming to exploit the frequent EGFR overexpression observed in a subset of patients [57]. This evidence concerns the gene EPCAM and neoplasm.